Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis
2018-001896-19Phase 2Active
- Sponsor
- Immunic Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing vidofludimus calcium with placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety and tolerability endpoint. Started Oct 2018; status: active.
02
Drugs
vidofludimus calcium
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2018-001896-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001896-19.